Literature DB >> 23529472

Use of glucosamine and chondroitin supplements and risk of colorectal cancer.

E D Kantor1, J W Lampe, U Peters, D D Shen, T L Vaughan, E White.   

Abstract

PURPOSE: Glucosamine and chondroitin are non-vitamin, non-mineral supplements which have anti-inflammatory properties. These supplements are typically used for joint pain and osteoarthritis and are commonly taken as either glucosamine alone or glucosamine plus chondroitin. An exploratory analysis conducted within the VITamins And Lifestyle (VITAL) study observed any use of glucosamine and chondroitin to be associated with reduced risk of colorectal cancer (CRC) after 5 years of follow-up.
METHODS: With two additional years of follow-up, we have studied these associations in greater depth, including associations by frequency/duration of use and by formulation, and have evaluated whether observed associations are modified by factors associated with inflammation. Participants include 75,137 western Washington residents aged 50-76 who completed the mailed VITAL questionnaire between 2000 and 2002. Use of glucosamine and chondroitin was ascertained by questions about supplement use during the 10-year period prior to baseline, and participants were followed for CRC through 2008 (n = 557). Cox regression was used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs).
RESULTS: Persons reporting use of glucosamine + chondroitin on 4+ days/week for 3+ years had a non-statistically significant 45 % lower CRC risk than non-users (HR: 0.55; 95 % CI 0.30-1.01; p-trend: 0.16). This association varied by body mass index (p-interaction: 0.006), with inverse association observed among the overweight/obese (p-trend: 0.02), but not among the underweight/normal weight. Use of glucosamine alone was not significantly associated with CRC risk.
CONCLUSIONS: There is great need to identify safe and effective cancer preventive strategies, suggesting that glucosamine and chondroitin may merit further attention as a potential chemopreventive agent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529472      PMCID: PMC3671752          DOI: 10.1007/s10552-013-0192-2

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  44 in total

Review 1.  EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).

Authors:  K M Jordan; N K Arden; M Doherty; B Bannwarth; J W J Bijlsma; P Dieppe; K Gunther; H Hauselmann; G Herrero-Beaumont; P Kaklamanis; S Lohmander; B Leeb; M Lequesne; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; U Serni; B Swoboda; G Verbruggen; I Zimmerman-Gorska; M Dougados
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

2.  Elevated C-reactive protein levels in overweight and obese adults.

Authors:  M Visser; L M Bouter; G M McQuillan; M H Wener; T B Harris
Journal:  JAMA       Date:  1999-12-08       Impact factor: 56.272

3.  Use of glucosamine and chondroitin in relation to mortality.

Authors:  Griffith A Bell; Elizabeth D Kantor; Johanna W Lampe; Danny D Shen; Emily White
Journal:  Eur J Epidemiol       Date:  2012-07-25       Impact factor: 8.082

4.  Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes.

Authors:  R Largo; M A Alvarez-Soria; I Díez-Ortego; E Calvo; O Sánchez-Pernaute; J Egido; G Herrero-Beaumont
Journal:  Osteoarthritis Cartilage       Date:  2003-04       Impact factor: 6.576

Review 5.  Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis.

Authors:  T E McAlindon; M P LaValley; J P Gulin; D T Felson
Journal:  JAMA       Date:  2000-03-15       Impact factor: 56.272

6.  Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats.

Authors:  Y Hori; J Hoshino; C Yamazaki; T Sekiguchi; S Miyauchi; K Horie
Journal:  Jpn J Pharmacol       Date:  2001-02

7.  Reliability and validity of self-report of vitamin and mineral supplement use in the vitamins and lifestyle study.

Authors:  Jessie Satia-Abouta; Ruth E Patterson; Irena B King; Kayla L Stratton; Ann L Shattuck; Alan R Kristal; John D Potter; Mark D Thornquist; Emily White
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

Review 8.  Chronic inflammation: a common and important factor in the pathogenesis of neoplasia.

Authors:  David Schottenfeld; Jennifer Beebe-Dimmer
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

9.  VITamins And Lifestyle cohort study: study design and characteristics of supplement users.

Authors:  Emily White; Ruth E Patterson; Alan R Kristal; Mark Thornquist; Irena King; Ann L Shattuck; Ilonka Evans; Jessie Satia-Abouta; Alyson J Littman; John D Potter
Journal:  Am J Epidemiol       Date:  2004-01-01       Impact factor: 4.897

10.  Association between use of specialty dietary supplements and C-reactive protein concentrations.

Authors:  Elizabeth D Kantor; Johanna W Lampe; Thomas L Vaughan; Ulrike Peters; Colin D Rehm; Emily White
Journal:  Am J Epidemiol       Date:  2012-11-08       Impact factor: 4.897

View more
  16 in total

1.  Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study.

Authors:  Elizabeth D Kantor; Xuehong Zhang; Kana Wu; Lisa B Signorello; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2016-07-18       Impact factor: 7.396

Review 2.  The Role of Glucosamine and Chondroitin Sulfate in the Prevention of Colorectal Cancer: A Systematic Review.

Authors:  Asma A Khan; Vij Mannan; Muhammad Ahad Pervaiz; Aqsa Akram; Elina S Momin; Muhammad Sanusi; Tejasvi Kashyap; Abeer O Elshaikh
Journal:  Cureus       Date:  2022-05-27

3.  Glucosamine Use and Risk of Colorectal Cancer: Results from UK Biobank.

Authors:  Elizabeth D Kantor; Kelli O'Connell; Peter S Liang; Sandi L Navarro; Edward L Giovannucci; Mengmeng Du
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-03-01       Impact factor: 4.090

4.  Differential effects of glucose and N-acetylglucosamine on genome instability.

Authors:  Yuan-Sheng Hsu; Pei-Jung Wu; Yung-Ming Jeng; Chun-Mei Hu; Wen-Hwa Lee
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

5.  Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort.

Authors:  Elizabeth D Kantor; Christina C Newton; Edward L Giovannucci; Marjorie L McCullough; Peter T Campbell; Eric J Jacobs
Journal:  Cancer Causes Control       Date:  2018-02-06       Impact factor: 2.506

6.  Simultaneous presentation of pancreatic cancer in a genetically unrelated couple.

Authors:  Mahender R Yellu; Olugbenga Olowokure
Journal:  BMJ Case Rep       Date:  2015-11-18

7.  Glucosamine and Chondroitin Use in Relation to C-Reactive Protein Concentration: Results by Supplement Form, Formulation, and Dose.

Authors:  Elizabeth D Kantor; Kelli O'Connell; Mengmeng Du; Chao Cao; Xuehong Zhang; Dong Hoon Lee; Yin Cao; Edward L Giovannucci
Journal:  J Altern Complement Med       Date:  2020-12-07       Impact factor: 2.579

8.  Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp.

Authors:  Dong Hoon Lee; Chao Cao; Yin Cao; Edward L Giovannucci; Elizabeth D Kantor; Xiaoyu Zong; Xuehong Zhang; Kelli O'Connell; Mingyang Song; Kana Wu; Mengmeng Du
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-14       Impact factor: 4.254

9.  Impact of Glucosamine Supplementation on Gut Health.

Authors:  Jessica M Moon; Peter Finnegan; Richard A Stecker; Hanna Lee; Kayla M Ratliff; Ralf Jäger; Martin Purpura; Carolyn M Slupsky; Maria L Marco; Craig J Wissent; Jason Theodosakis; Chad M Kerksick
Journal:  Nutrients       Date:  2021-06-24       Impact factor: 5.717

10.  The novel IGF-IR/Akt-dependent anticancer activities of glucosamine.

Authors:  Ki-Hoon Song; Ju-Hee Kang; Jong-Kyu Woo; Jeong-Seok Nam; Hye-Young Min; Ho-Young Lee; Soo-Youl Kim; Seung-Hyun Oh
Journal:  BMC Cancer       Date:  2014-01-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.